Enhertu for HER2-Low Breast Cancer: Patient-Reported Outcomes
Enhertu for HER2-Low Breast Cancer: Patient-Reported Outcomes
Enhertu for HER2-Low Breast Cancer: Patient-Reported Outcomes
At the European Society for Medical Oncology Congress 2022, Dr. Naoto Ueno presented patient-reported quality-of-life outcomes from the DESTINY-Breast04 study, which found that compared to doctors’ choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.Listen to the episode to her Dr. Ueno explain:
how the researchers assessed quality of life
the results showing that Enhertu offered better quality of life than the doctors’ choice of chemotherapy
differences in side effects between Enhertu and chemotherapy
From The Podcast
Breastcancer.org Podcast
Breastcancer.org is a nonprofit organization dedicated to providing the most reliable, complete, and up-to-date information about breast cancer. Our mission is to help women and their loved ones make sense of the complex medical and personal information about breast cancer, so they can make the best decisions for their lives. Breastcancer.org podcasts offer unique insights on prevention, treatment, research, and other breast cancer topics from our medical experts and invited guests.Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Episode Tags
Claim and edit this page to your liking.
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us